Last reviewed · How we verify
STX-0712
At a glance
| Generic name | STX-0712 |
|---|---|
| Sponsor | Solu Therapeutics, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STX-0712 CI brief — competitive landscape report
- STX-0712 updates RSS · CI watch RSS
- Solu Therapeutics, Inc portfolio CI